Skeletal responses to romosozumab after 12 months of denosumab

Romosozumab, a monoclonal anti‐sclerostin antibody that has the dual effect of increasing bone formation and decreasing bone resorption, reduces fracture risk within 12 months. In a post hoc, exploratory analysis, we evaluated the effects of romosozumab after 12 months of denosumab in postmenopausal...

Descripción completa

Detalles Bibliográficos
Autores principales: McClung, Michael R., Bolognese, Michael A., Brown, Jacques P., Reginster, Jean‐Yves, Langdahl, Bente L., Shi, Yifei, Timoshanko, Jen, Libanati, Cesar, Chines, Arkadi, Oates, Mary K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260819/
https://www.ncbi.nlm.nih.gov/pubmed/34258507
http://dx.doi.org/10.1002/jbm4.10512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260819/
https://www.ncbi.nlm.nih.gov/pubmed/34258507
http://dx.doi.org/10.1002/jbm4.10512

Ejemplares similares